12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VX-175 (GW433908): Began Phase III studies

A separate 48-week international trial of >600 treatment-naive patients will compare 3 VX-175 tablets given once per day in combination with Abbott Laboratories' Norvir ritonavir protease inhibitor with Viracept treatment, both...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >